In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice

Navindra P. Seeram\textsuperscript{a,*}, Lynn S. Adams\textsuperscript{a}, Susanne M. Henning\textsuperscript{a}, Yantao Niu\textsuperscript{a}, Yanjun Zhang\textsuperscript{b,c}, Muraleedharan G. Nair\textsuperscript{b,c}, David Heber\textsuperscript{a}

\textsuperscript{a}Center for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
\textsuperscript{b}Bioactive Natural Products and Phytoceuticals, National Food Safety and Toxicology Center, Michigan State University, East Lansing, MI 48824, USA
\textsuperscript{c}Department of Horticulture, Michigan State University, East Lansing, MI 48824, USA

Received 10 December 2004

Abstract

Pomegranate (\textit{Punica granatum} L.) fruits are widely consumed as juice (PJ). The potent antioxidant and anti-atherosclerotic activities of PJ are attributed to its polyphenols including punicalagin, the major fruit ellagitannin, and ellagic acid (EA). Punicalagin is the major antioxidant polyphenol ingredient in PJ. Punicalagin, EA, a standardized total pomegranate tannin (TPT) extract and PJ were evaluated for antiproliferative, apoptotic and antioxidant activities. Punicalagin, EA and TPT were evaluated for antiproliferative activity at 12.5–100 \textmu g/ml on human oral (KB, CAL27), colon (HT-29, HCT116, SW480, SW620) and prostate (RWPE-1, 22Rv1) tumor cells. Punicalagin, EA and TPT were evaluated at 100 \textmu g/ml concentrations for apoptotic effects and at 10 \textmu g/ml concentrations for antioxidant properties. However, to evaluate the synergistic and/or additive contributions from other PJ phytochemicals, PJ was tested at concentrations normalized to deliver equivalent amounts of punicalagin (w/w). Apoptotic effects were evaluated against the HT-29 and HCT116 colon cancer cell lines. Antioxidant effects were evaluated using inhibition of lipid peroxidation and Trolox equivalent antioxidant capacity (TEAC) assays. Pomegranate juice showed greatest antiproliferative activity against all cell lines by inhibiting proliferation from 30\% to 100\%. At 100 \textmu g/ml, PJ, EA, punicalagin and TPT induced apoptosis in HT-29 colon cells. However, in the HCT116 colon cells, EA, punicalagin and TPT but not PJ induced apoptosis. The trend in antioxidant activity was PJ > TPT > punicalagin > EA. The superior bioactivity of PJ compared to its purified polyphenols illustrated the multifactorial effects and chemical synergy of the action of multiple compounds compared to single purified active ingredients.

\textcopyright 2005 Elsevier Inc. All rights reserved.

Keywords: Pomegranates; Punicalagin; Ellagic acid; Antiproliferative; Apoptosis; Antioxidant

1. Introduction

Epidemiological studies suggest that a reduced risk of cancer is associated with the consumption of a phytochemical-rich diet that includes fruits and vegetables [1]. Fresh and processed fruits and food products contain high levels of a diverse range of phytochemicals of which polyphenols including hydrolyzable tannins [ellagitannins (ETs) and gallotannins] and condensed tannins (proanthocyanidins), and anthocyanins and other flavonoids make up a large proportion [2–4]. Suggested mechanisms of anticancer effects of polyphenols include antioxidant, anti-inflammatory and antiproliferative activities as well as their effects on subcellular signaling pathways, induction of cell-cycle arrest and apoptosis [5,6].

Pomegranate (\textit{Punica granatum} L.) fruits are widely consumed fresh and in beverage forms as juice and wines [7]. Commercial pomegranate juice (PJ) shows potent antioxidant and anti-atherosclerotic properties attributed to its high content of polyphenols including ellagic acid (EA) in its free and bound forms [as ETs and EA glycosides.
(EAGs), gallotannins and anthocyanins (cyanidin, delphinidin and pelargonidin glycosides), and other flavonoids (quercetin, kaempferol and luteolin glycosides) [7–12]. The most abundant of these polyphenols is punicalagin (Fig. 1), an ET implicated as the bioactive constituent responsible for >50% of the juice’s potent antioxidant activity [7]. Punicalagin is abundant in the fruit husk and during processing is extracted into PJ in significant quantities reaching levels of >2 g/L juice [7,11–13].

We are interested in the potential health benefits of phytochemicals and in evaluating the multifactorial effects and chemical synergy of the action of multiple compounds, as found naturally in their unique compositions in foods compared to single purified active compounds [14]. Because pomegranates are widely consumed and implicated with potential human health benefits [8,15], we have investigated the antiproliferative, apoptotic and antioxidant activities [lipid peroxidation inhibitory and Trolox equivalent antioxidant capacity (TEAC)] of its polyphenols. Pomegranate was evaluated in the form of PJ, a popularly consumed beverage, as a standardized total pomegranate tannin (TPT) extract (contains 85% punicalagin anomers, 1.3% EA, ~12% minor ETs and EAGs) [13], and as its reported active ingredients, punicalagin and EA.

Ellagic acid has been previously shown to exhibit anticarcinogenic properties such as induction of cell-cycle arrest and apoptosis, as well as the inhibition of tumor formation and growth in animals [16–18]. Hydrolyzable and condensed tannins have also been reported to show in vitro and in vivo anticancer properties [19,20]. However, this is the first report on the evaluation of PJ and TPT and their major purified polyphenols, punicalagin and EA, for antiproliferative activity against this panel of human oral (KB, CAL27), colon (HT-29, HCT116, SW480, SW620) and prostate (RWPE-1, 22Rv1) cancer cell lines. This is also the first report on the inhibition of lipid peroxidation by pomegranate polyphenols using a model of liposome oxidation by fluorescence spectroscopy and on the evaluation of their apoptotic effects against human colon cancer cells.

2. Methods and materials

2.1. General materials

All solvents were high-performance liquid chromatography (HPLC) grade and purchased from Fisher Scientific (Tustin, CA). Dimethylsulphoxide (DMSO), dimethyl formamide and ellagic acid (EA) were purchased from Sigma Aldrich (St. Louis, MO). Pomegranate juice (POM Wonderful LLC, Los Angeles, CA, USA) is commercially available for human consumption and was used in concentra- 
tion (contains 1.74 mg/ml punicalagin and 0.14 mg/ml EA; quantification data not shown).

2.2. Purification of TPT extract and punicalagin

Ellagittannins were purified from fruit husk as previously reported and analyzed for purity by HPLC and liquid chromatography electrospray ionization mass spectroscopy (LC-ESI/MS) [13]. Total pomegranate tannins contains 85% punicalagin anomers (M-H m/z 1083), 1.3% EA (M-H m/z 301) and ~12% minor ETs and EAGs [13].

2.3. Cell culture materials

The KB and CAL27 oral cancer, SW480, SW620, HT29 and HCT116 colon cancer and RWPE-1 prostate cancer cell lines were obtained from American Type Culture Collection (ATCC, Rockville, MD). The 22Rv1 prostate cancer cell line was obtained from the laboratory of P. Cohen (Division of Pediatric Endocrinology, UCLA Medical Center, Los Angeles, CA). KB oral cancer cells were grown in minimum essential medium (MEM); CAL27 oral cancer cells were grown in Dulbecco’s minimum essential medium (DMEM); SW480 and SW620 colon cancer cells and 22Rv1 prostate cancer cells were grown in RPMI 1640; HT-29 and HCT116 colon cancer cells were grown in McCoy’s 5A medium (modified). All media contained 10% fetal bovine serum (FBS) in the presence of 100 U/ml penicillin and 0.1 g/L streptomycin. RWPE-1 prostate cells were grown in Defined Keratinocyte Serum Free Medium (DKSFM) containing epidermal growth factor (EGF), insulin and fibroblast growth factor (FGF). Cells were incubated at 37°C with 95% air and 5% CO2. All cells were maintained below passage 20 and used in experiments during the linear phase of growth.

2.4. Cell proliferation assay

Proliferation was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Technical Bulletin #288, Promega, Madison, WI). When added to cells, the assay reagent produces luminescence in the presence of ATP from viable cells. Cells were plated in 96-well plates at a density of 10,000 cells/well and incubated for 24 h. Test samples were solubilized in DMSO by sonication, filter sterilized and diluted with media to the desired treatment concentration. Cells were treated with 100 μL control media, ascorbic acid (100 μM, used as an antioxidant standard) or
2.5. Assessment of apoptosis

Apoptosis was assessed using the Cell Death Detection ELISA$^{\text{PLUS}}$ Assay (Boehringer Mannheim, Indianapolis, IN). This assay is a photometric enzyme-linked immunoassay that quantitatively measures the internucleosomal degradation of DNA, which occurs during apoptosis. Specifically, the assay detects histone-associated mono- and oligonucleosomes, which are indicators of apoptosis. HT-29 and HCT116 cells were plated in 60-mm dishes at a density of 100,000 cells/dish and allowed to attach for 24 h. Cells were treated with vehicle control (100% DMSO; 0.3% final concentration), EA, punicalagin, TPT or PJ (100 μg/ml) for 48 h. Following treatments, nonadherent cells were collected and pelleted at 200 × g for 10 min. The supernatant was discarded; the cell pellet was washed with cold calcium/magnesium-free phosphate buffered saline (CMF-PBS) and centrifuged. Adherent cells were washed with CMF-PBS (137 mmol/L sodium chloride, 1.5 mmol/L potassium phosphate, 7.2 mmol/L sodium phosphate, 2.7 mmol/L potassium chloride, pH 7.4), trypsinized, collected and combined with nonadherent cells into a total of 1 ml DMEM. Both live and dead cells were then counted via trypan blue exclusion (Pierce, Rockford, IL), and equal number of cells were added to the microtiter plate for all treatment groups, and apoptosis assay was performed according to the manufacturer’s instructions. Data are expressed as absorbance at 405 nm of each sample over vehicle controls as follows: treatment value–blank/vehicle value–blank.

2.6. Inhibition of lipid peroxidation

The assay was conducted by analysis of model liposome oxidation using fluorescence spectroscopy as previously reported [21]. Briefly, the lipid, 1-stearoyl-2-linoleoyl-sn-glycerol-3-phosphocholine, and fluorescent probe, 3-[p-(6-phenyl)-1,3,5-hexatrienyl]-phenylpropionic acid, were combined in dimethyl formamide and used to prepare large unilamellar vesicles (LUVs). The final assay volume combined HEPES buffer, test sample or DMSO (control) and a 20-μl aliquot of liposome suspension in a test tube. Peroxidation was initiated by addition of FeCl$_2$·4H$_2$O (0.5 mM) for positive controls, [tert-butylhydroquinone (TBHQ), butylated-hydroxyanisole (BHA) and butylated-hydroxytoluene (BHT); all at 10 μM] and test samples (all at 10 μg/ml; 20-μl aliquot volume). Each sample was assayed in triplicate. Fluorescence was measured at 384 nm and monitored at 0, 1, 3 and every 3 min thereafter up to 21 min using a Turner Model 450 Digital Fluorometer (Barnstead Thermolyne, Dubuque, IA). The decrease of relative fluorescence intensity with time indicated the rate of peroxidation according to the following formula: % relative fluorescence = (F$_{ta}$ + F$_{tb}$)/(F$_{0a}$ + F$_{0b}$). F$_{ta}$ and F$_{tb}$ represent the two measurement of the fluorescence of sample at selected times (0, 3, 6 min, etc.). F$_{0a}$ and F$_{0b}$ represent the two measurements at time 0 of the same sample.

2.7. Trolox equivalent antioxidative capacity

The assay was performed as previously reported [22]. Briefly, 22’-azinobis(3-thylbenzothiazline-6-sulfonic acid)-diammonium salt (ABTS) radical cations were prepared by adding solid manganese dioxide (80 mg) to a 5-mM aqueous stock solution of ABTS$^+$ (20 ml using a 75-mM Na/K buffer of pH 7). Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), a water soluble analog of vitamin E, was used as an antioxidant standard. A standard calibration curve was constructed for Trolox at 0, 50, 100, 150, 200, 250, 300, 350 μM concentrations. Samples (10 μg/ml concentrations) were mixed with 200 μl of ABTS$^+$ radical cation solution in 96-well plates and absorbance was read (at 750 nm) after 5, 15, 30, 45, 60, 75 and 90 min in a ThermoMax microplate reader (Molecular Devices, Sunnyvale, CA). Trolox equivalent antioxidant capacity values were calculated as reading×volume/1000. Trolox equivalents (in μM) were derived from the standard curve at 5 min of incubation.

2.8. Statistics

Data for the antiproliferative and apoptosis assays were analyzed by either Student’s $t$ test, one-way ANOVA followed by Dunnett’s multiple range test ($\alpha=0.05$) with GraphPad Prism 3.0 (GraphPad Software) as appropriate.

3. Results

The biological properties associated with pomegranate fruits [7–10] prompted us to evaluate their major phytochemical ingredients as single purified compounds, punicalagin and EA (Fig. 1), and as combinations, TPT and PJ. We have previously reported that TPT contains 85% punicalagin, 1.3% EA hexoside and minor EAGs and ETs (punicalin and gallic acid) [13]. The minor pomegranate ETs and EAGs were not quantified in TPT due to the
unavailability of commercial standards. The PJ used in our experiments contained 1.74 mg/ml punicalagin and 0.14 mg/ml EA.

Test samples were evaluated for antiproliferative activity against human oral (KB, CAL27), colon (SW460; SW620; HT-29; HCT116) and prostate (RWPE-1; 22Rv1) tumor cells. At concentrations normalized to deliver equivalent amounts of the major pomegranate polyphenol, punicalagin (w/w), PJ showed the greatest antiproliferative activity against all cell lines by inhibiting proliferation from 30% to 100% at treatments between 12.5 and 100 µg/ml (Figs. 2–4). Punicalagin, EA and TPT inhibited cell proliferation in a dose-dependent manner in all cell lines tested, but to a lesser degree than PJ. In KB oral cancer cells, EA inhibited proliferation from 45% to 88%, punicalagin from 0% to 42% and TPT from 0% to 27% (Fig. 2A). In CAL27 oral cancer cells, EA inhibited cell proliferation from 26% to 69%, punicalagin from 10% to 96% and TPT from 17% to 97% (Fig. 2B). SW480

Fig. 2. Antiproliferative activities of punicalagin(-), EA(-) and PJ(-) against human oral tumor cell lines: (A) KB; (B) CAL27. Cells were exposed to punicalagin, EA or TPT (at 100–12.5 µg/ml concentrations) and PJ (normalized to punicalagin content) for 48 h. Data are expressed as percentage of untreated cells, mean±S.E. (n=3). Asterisk indicates a significant difference compared to untreated controls, P≤.01, two-tailed t test.

Fig. 3. Antiproliferative activities of punicalagin (-), EA (-) and PJ (-) against human colon tumor cell lines: (A) SW460; (B) SW620; (C) HT29; (D) HCT116. Cells were exposed to punicalagin, EA or TPT (at 100–12.5 µg/ml concentrations) and PJ (normalized to punicalagin content) for 48 h. Data are expressed as percentage of untreated cells, mean±S.E. (n=3). Asterisk indicates a significant difference compared to untreated controls, P≤.05, two-tailed t test.
nonmetastatic colon cancer cells also showed sensitivity to pomegranate polyphenols with EA inhibiting cell proliferation from 49% to 76%, punicalagin from 1% to 65% and TPT from 1% to 67% (Fig. 3A). In SW620 metastatic colon cancer cells, EA inhibited proliferation from 14% to 35%, punicalagin from 0% to 57% and TPT from 0.02% to 40% (Fig. 3B). Proliferation of HT-29 colon cancer cells was inhibited from 0% to 21% by EA, from 1% to 55% by punicalagin and from 2% to 71% by TPT (Fig. 3C), and in HCT116 colon cancer cells, EA induced inhibition of proliferation from 53% to 87%, punicalagin from 0% to 72% and TPT from 13% to 87% (Fig. 3D). Similarly, in RWPE-1 immortalized prostate epithelial cells, EA inhibited proliferation from 78% to 92%, punicalagin from 64% to 94% and TPT from 44% to 88% (Fig. 4A). In 22Rv1 metastatic prostate cancer cells, EA inhibited proliferation from 43% to 94%, punicalagin from 68% to 90% and TPT from 47% to 89% at treatments between 12.5 and 100 µg/ml (Fig. 4B).

Because of our interest in colon cancer, the apoptotic effect of PJ and its purified polyphenols on the HT-29 and HCT116 colon cancer cell lines was evaluated to ascertain whether the observed reduction in viable cell number was due to the induction of apoptosis (Fig. 5). At doses held equivalent to that found in PJ, punicalagin, EA and TPT did not exhibit apoptotic activity in HT-29 and HCT116 colon cancer cell lines (data not shown). However, when treated at equivalent doses of 100 µg/ml, PJ, EA, punicalagin and TPT induced apoptosis in HT-29 cells by 2.66-, 2.44-, 2.65- and 2.59-fold, respectively, over vehicle controls. Similarly, in the HCT116 cells, EA, punicalagin and TPT induced apoptosis by 2.85-, 1.52- and 2.87-fold over vehicle controls. Interestingly, although PJ decreased viable cell number at 100 µg/ml, it did not exhibit significant apoptotic activity in this cell line.

Punicalagin, EA, TPT and PJ (all at 10 µg/ml concentrations) were also evaluated for the ability to inhibit lipid peroxidation induced by Fe (II) ions in a liposomal model and for TEAC. The abilities of the samples to inhibit lipid peroxidation were compared to that of the commercial synthetic antioxidants, TBHQ, BHT and BHA (all at 10 µM concentrations) (Fig. 6A). In the lipid peroxidation assay, the relative decrease in fluorescence showed that PJ was the most active sample among the pomegranate polyphenols tested (Fig. 6B). In the TEAC assay, PJ, TPT, punicalagin and EA had values of 25,591, 100, 90 and 40 µM Trolox equivalents, respectively. Trolox equivalent antioxidant capacity is the concentration of Trolox required to give the same antioxidant capacity as 1 mM test substance. The total antioxidant activity of PJ was equivalent to that of a solution of 31.8 mM of Trolox calculated experimentally by the TEAC method. The order of antioxidative potency of the pomegranate polyphenols in our assays was PJ>TPT>punicalagin>EA, showing that
PJ is a more effective antioxidant than its separated and purified components.

4. Discussion

Pomegranate fruits are widely consumed in fresh and beverage forms and have been used extensively in ancient cultures for various medicinal properties [23]. Pomegranate juice and extracts have been shown to have potent in vitro antioxidant[7,24] and in vivo anti-atherosclerotic properties[8,9,15], attributed to its high content of polyphenols including ETs and EA. Recently, there have also been numerous reports on the in vitro and in vivo anticancer properties of pomegranates [10,25–30]. The major pomegranate ET, punicalagin, is reported as the active ingredient contributing largely to the observed antioxidant properties of PJ, as previously reported [7,24].

Our finding that PJ is more potent than its separated and individual polyphenols suggests synergistic and/or additive effects from the other phytochemicals present in PJ. This finding is not surprising, as PJ also contains proanthocyanidins, anthocyanins (glycosides of delphinidin,peonin and cyanin) and flavonoid glycosides [10–13], phytochemicals that have all been shown to have antioxidant and antiproliferative activities [14,21]. The limitations in this work are true of most in vitro studies. Cell line specific sensitivity and reactions have been shown in many trials and this should be considered when evaluating experimental results. Additionally, in vitro trials do not always reflect the outcome of in vivo studies either; however, in vitro experiments can be a valuable screening tool for future animal and human studies.

Cancer cells exist under a state of oxidative stress, as this increases their survival potential by inducing mutations [34], activating redox signaling that may lead to the inactivation of tumor suppressor genes such as p53 [35] and the activation of prosurvival factors such as NFκB and AP-1 [36]. Mild levels of reactive oxygen species (ROS) have been shown to induce proliferation in cancer cells [37,38]. Therefore, foods rich in antioxidant phytochemicals are important for the prevention of diseases related to oxidant stress such as heart disease and cancer. In this study, our focus on cancer cell lines investigated the potential of pomegranate juice and its purified polyphenols as anticancer agents by evaluating their effect on oxidation, viable cell number and the sensitivity of colon cancer cells to apoptosis.

Other natural antioxidants, such as curcumin, have been shown to stimulate the expression of the tumor suppressor gene p53 [39]. Vitamin E and quercetin also show promise as anticancer agents as they exhibit inhibition of mutant p53 in human cancer cell lines [40–42]. In addition, vitamins C and E were shown to decrease nuclear binding and activation of NFkB and AP-1 in LNCaP prostate cancer cells. In our studies, we show that PJ and its purified polyphenols are potent antioxidants which may be a mechanism whereby they inhibit cancer cell proliferation and induce cancer cells to undergo apoptosis. Although the purified polyphenols showed significant antiproliferative, apoptotic and antioxidant effects alone,
the superior bioactivity of PJ suggests multifactorial effects and chemical synergy of the action of multiple compounds compared to single purified active ingredients.

Acknowledgment

Funding for this project was provided by the Center for Dietary Supplement Research: Botanicals (CDSRB) and the Clinical Nutrition Research Unit (CNRU) at the Center for Human Nutrition, UCLA from NIH/NCCAM grant P50AT00151 and NCI grant PO1CA42710, respectively. L.S.A. is currently on a training grant fellowship from NIH/NIDDK Award #2T32DK007688.

References